Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Infection01:20

Infection

11.6K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
11.6K
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

524
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
524
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

676
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
676
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.5K
The pathophysiology of pneumonia involves the following steps:
2.5K
Stages of Infection01:26

Stages of Infection

64.7K
Stages of infection describe what happens to a susceptible host once a pathogen invades the human body. The stages of infection are incubation, prodromal, illness, stage of decline, and convalescence. The incubation stage is the period from exposure to a pathogen until symptoms start. The infected person is unaware of impending illness as the pathogens grow and multiply within the body. The duration may vary depending on the type of infection. The incubation period of measles averages ten to...
64.7K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

2.6K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

CSF Testing for Neuroinvasive West Nile Virus and Measures to Improve Guideline Adherence.

Neurology. Clinical practice·2026
Same author

Potassium-solubilizing bacteria from tropical forest soils enhance potassium and phosphorus uptake in maize.

Frontiers in microbiology·2026
Same author

MRI-based tumor signatures as prognostic biomarkers in oral tongue squamous cell carcinoma.

Frontiers in oncology·2026
Same author

Symbiont dominance and microbiome dysbiosis in wheat-aphid revealed through 16 S rRNA gene amplicon sequencing analysis.

World journal of microbiology & biotechnology·2026
Same author

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results.

Journal of inherited metabolic disease·2026
Same author

Comparison of Clinical and Pathological T Staging in Gingivobuccal Complex Cancers-A Retrospective Analysis.

Indian journal of surgical oncology·2026
Same journal

Association of sleep duration with Alzheimer's disease and cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 8, 2026

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

11.5K

Ciencia básica y patogénesis

Isha Verma1, Monica Kumar1, Kirpal Bains1

  • 1Nova Southeastern University, Clearwater, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La semaglutida (Ozempic) muestra potencial en el tratamiento de la enfermedad de Alzheimer al mejorar la resistencia a la insulina y reducir la neuroinflamación. Se necesita más investigación para confirmar su eficacia y seguridad a largo plazo en pacientes con EA.

Palabras clave:
semaglutidaOzempicenfermedad de Alzheimerresistencia a la insulinaneurodegeneraciónagonista del receptor GLP-1

Más Videos Relacionados

A Precise Pathogen Delivery and Recovery System for Murine Models of Secondary Bacterial Pneumonia
13:45

A Precise Pathogen Delivery and Recovery System for Murine Models of Secondary Bacterial Pneumonia

Published on: September 21, 2019

6.0K
Using a Bacterial Pathogen to Probe for Cellular and Organismic-level Host Responses
08:38

Using a Bacterial Pathogen to Probe for Cellular and Organismic-level Host Responses

Published on: February 22, 2019

6.3K

Videos de Experimentos Relacionados

Last Updated: Jan 8, 2026

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

11.5K
A Precise Pathogen Delivery and Recovery System for Murine Models of Secondary Bacterial Pneumonia
13:45

A Precise Pathogen Delivery and Recovery System for Murine Models of Secondary Bacterial Pneumonia

Published on: September 21, 2019

6.0K
Using a Bacterial Pathogen to Probe for Cellular and Organismic-level Host Responses
08:38

Using a Bacterial Pathogen to Probe for Cellular and Organismic-level Host Responses

Published on: February 22, 2019

6.3K

Área de la Ciencia:

  • Neurociencia; Endocrinología; Farmacología

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) es un trastorno neurodegenerativo con opciones terapéuticas limitadas.; La evidencia emergente vincula la resistencia a la insulina (RI), común en la diabetes tipo 2, con la patología de la EA, incluida la neuroinflamación y las agregaciones proteicas características.; Los tratamientos actuales para la EA solo ofrecen un alivio sintomático temporal.

Objetivo del estudio:

  • Sintetizar la investigación actual sobre los efectos de la semaglutida, un agonista del receptor GLP-1, sobre la resistencia a la insulina y la neurodegeneración en la enfermedad de Alzheimer.; Evaluar el potencial de la semaglutida como un agente terapéutico de doble acción para la disfunción metabólica y el deterioro cognitivo en la EA.

Principales métodos:

  • Se realizó una búsqueda exhaustiva de literatura en PubMed y Google Scholar (2012-2024) utilizando las palabras clave: "semaglutida", "Ozempic", "agonista del receptor GLP-1", "resistencia a la insulina" y "enfermedad de Alzheimer".; Los criterios de inclusión se centraron en ensayos clínicos revisados por pares, metaanálisis y estudios preclínicos en inglés, que examinaron el impacto de la semaglutida en la RI y la EA.; Los criterios de exclusión eliminaron estudios no relevantes para los efectos de la semaglutida en la EA, artículos no revisados por pares y estudios no humanos.

Principales resultados:

  • La semaglutida mejora la sensibilidad a la insulina, reduce la inflamación y mejora el metabolismo de la glucosa, y potencialmente cruza la barrera hematoencefálica para afectar la señalización de la insulina neuronal.; Los estudios indican que la semaglutida puede reducir la patología de amiloide-β y tau, disminuir la neuroinflamación y mejorar la función cognitiva.; Los ensayos clínicos tempranos (por ejemplo, ELAD) y los estudios observacionales sugieren que los agonistas del receptor GLP-1 pueden reducir el riesgo de EA y mejorar los resultados, con ensayos en curso (por ejemplo, EVOKE) que investigan la eficacia en la EA temprana.

Conclusiones:

  • La semaglutida demuestra resultados preclínicos y clínicos tempranos prometedores para la enfermedad de Alzheimer, particularmente en el abordaje de la neurodegeneración relacionada con la RI.; Se requiere una mayor investigación para determinar la seguridad a largo plazo, la dosificación óptima y el impacto definitivo en la progresión de la EA.; La semaglutida tiene potencial como agente terapéutico de doble propósito tanto para trastornos metabólicos como para afecciones neurodegenerativas como la EA.